Teatini Ugo, Romei Longhena Giorgio
Nefrologia e Dialisi, ASST Rhodense, Milano, Italia.
G Ital Nefrol. 2017 Sep 28;34(5):89-101.
Uremic status results from a malfunctioning of kidneys due to the accumulation of compounds which, under normal conditions, are excreted or metabolized by the kidneys. If these compounds are biologically active, they are called uremic toxins. Such compounds have toxic effects on the cardio-vascular system. An useful classification, published by the European Uremic Toxin Work Group (EUTox) is: 1) small water-soluble compounds; 2) protein-bound compounds; 3) the larger "middle molecules". High-flux membranes and more efficient treatment techniques, like HDF, improve the removal of uremic toxins in the middle molecular-weight range, and recent studies suggest that these strategies have better results on the morbidity and mortality. Today new membranes, medium cut-off membranes (MCO), with increased pore size, allow for the removal of higher molecular-weight toxins, such as kappa and lambda light chains and/or mediators of inflammation. For toxins in the 15 to 45 KD-size range, MCO membranes improve the removal in comparison with high-flux HD and/or HDF. Therefore MCO membrane simplifies the treatment of HD patients with a removal spectrum that extend the current possibilities of the best available therapies for End Stage Renal Disease.
尿毒症状态是由于肾脏功能失常导致的,这是由于在正常情况下会由肾脏排泄或代谢的化合物积累所致。如果这些化合物具有生物活性,它们就被称为尿毒症毒素。这类化合物对心血管系统具有毒性作用。欧洲尿毒症毒素工作组(EUTox)发布的一个有用分类是:1)小的水溶性化合物;2)与蛋白质结合的化合物;3)较大的“中分子”。高通量膜以及更高效的治疗技术,如血液透析滤过(HDF),能改善中分子量范围内尿毒症毒素的清除,并且最近的研究表明这些策略在发病率和死亡率方面有更好的效果。如今,孔径增大的新型膜,即中截留量膜(MCO),能够清除更高分子量的毒素,如κ和λ轻链以及/或炎症介质。对于15至45千道尔顿大小范围内的毒素,与高通量血液透析(HD)和/或血液透析滤过相比,MCO膜能改善清除效果。因此,MCO膜简化了对血液透析患者的治疗,其清除谱扩展了终末期肾病现有最佳疗法的当前可能性。